Eli Lilly Builds $1.5 Billion Orforglipron Inventory Ahead of April FDA Approval
Eli Lilly has stocked roughly $1.5 billion in Orforglipron inventory ahead of anticipated April FDA approval for its oral weight-loss pill. The inventory build and planned summer launch aim to position the pill as a convenient alternative to Zepbound while challenging Novo Nordisk’s Wegovy.
1. Inventory Build and Logistics
Eli Lilly has initiated a build of approximately $1.5 billion in Orforglipron inventory to ensure immediate availability post-clearance, positioning the company for a high-volume summer launch.
2. FDA Approval and Launch Plans
FDA approval is expected in April, with marketing campaigns and shipments scheduled to roll out as soon as clearance is granted to meet global demand.
3. Competitive Positioning
Orforglipron’s oral format is designed to offer a convenient alternative to injectable Zepbound, aiming to capture market share from Novo Nordisk’s early-mover Wegovy in the fast-growing weight-loss sector.